AzTrials
AzTrials

Colorectal CancerPhase 1NCT00096330

Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer

A Phase 1 study testing dietary intervention and folic acid in people with Colorectal Cancer, run by Roswell Park Cancer Institute at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the development of cancer. The use of folic acid may be effective in preventing colorectal cancer. Eating a diet rich in folic acid may prevent the development of colorectal cancer. Read more about this study

Who is it for?
Ages 40 to 72 yearsHealthy volunteers can take part
Conditions the study is for
Colorectal Cancer
What is being tested?
dietary intervention and folic acid
Type of treatment
Pill or oral medicine
How many people
20 participants
Where
1 siteUnited States
Study dates
Sep 2004to Mar 2008
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 72 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

DISEASE CHARACTERISTICS:

  • Healthy persons at increased risk for colorectal neoplasia due to 1 of the following reasons:
  • Personal history of colorectal adenomatous polyps
  • Family history of colorectal adenoma or adenocarcinoma
  • No history of multiple family members with colorectal neoplasia that is suggestive of dominant hereditary neoplasia

PATIENT CHARACTERISTICS:

Age

  • 40 to 72

Performance status

  • Ambulatory

Life expectancy

  • At least 6 months

Hematopoietic

  • No excessive bleeding or coagulation disorder

Hepatic

  • ALT or AST ≤ 2 times upper limit of normal
  • No unexplained elevated alkaline phosphatase

Renal

  • Creatinine ≤ 2.0 mg/dL

Cardiovascular

  • Homocysteine concentration ≤ 17um/L
  • No sustained blood pressure > 150/95 mm Hg for 3 consecutive readings

Other

  • Vitamin B_12 ≥ 250 pg/mL
  • Folate level ≤ 20 mg/dL
  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 4 weeks after study participation
  • No intestinal malabsorption or inflammatory bowel disease
  • No prior malignancy except nonmelanoma skin cancer
  • No calcium metabolism abnormalities or predisposing conditions, such as hyperparathyroidism
  • No untreated hyperthyroidism
  • No untreated insulin-requiring diabetes mellitus
  • No daily alcohol intake > 2 ½ shot glasses of whiskey or three 8 ounce glasses of beer or wine
  • No other serious illness that might limit life expectancy to < 6 months

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • None

Chemotherapy

  • None

Endocrine therapy

  • No concurrent hormone replacement therapy, including oral, transplanted, or injected contraceptives
  • Concurrent thyroid hormone replacement is allowed as long as the patient is euthyroid for 3 months

Radiotherapy

  • None

Surgery

  • No prior gastrointestinal surgery, including gastrectomy or small or large bowel resections
  • Prior appendectomy or surgery of the esophagus allowed

Other

  • More than 3 months since regular ingestion of ≥ 650 mg per day of aspirin (≥ 2 tablets of 325 mg regular strength OR > 1 tablet of 500 mg extra strength aspirin)
  • More than 3 months since regular daily ingestion of nonsteroidal anti-inflammatory drugs
  • At least 1 month since vitamin, mineral, or herbal supplementation
  • No other concurrent vitamin, mineral, or herbal supplementation
  • No concurrent anticoagulants
  • No concurrent sterol-binding resins (i.e., cholestyramine)
  • No other concurrent investigational drugs or medications that might alter rectal mucosal proliferation, folate metabolism, or renal/hepatic impairment
  • No concurrent weight control medications
  • No concurrent supplemental folate preparations containing > 400 mcg of folic acid per day
  • No concurrent lipid-lowering medications
  • The following concurrent statin drugs are allowed provided patient has been taking a stable dose for ≥ 1 month:
  • Atorvastatin 10 or 20 mg/day
  • Fluvastatin 20 or 40 mg/day
  • Lovastatin 10 or 20 mg/day
  • Pravastatin 10 or 20 mg/day
  • Simvastatin 5 or 10 mg/day

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Roswell Park Cancer Institute

    Buffalo, New York, 14263-0001

Other trials in United States

About this study

Official title: Phase I Clinical Study of Folate

RATIONALE: Chemoprevention therapy is the use of certain agents to try to prevent the development of cancer. The use of folic acid may be effective in preventing colorectal cancer. Eating a diet rich in folic acid may prevent the development of colorectal cancer.

PURPOSE: This randomized phase I trial is studying how well a folate-depleted diet works compared to a folate-supplemented diet in preventing colorectal cancer in patients who are at high risk for developing colorectal cancer.

Read the detailed description

OBJECTIVES:

Primary

  • Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints (e.g., genomic and gene-specific DNA methylation and DNA strand breaks) in rectal epithelial cells in patients at high risk for colorectal neoplasia.
  • Analyze the effects of these dietary interventions on folate-related DNA endpoints (e.g., genomic and gene-specific DNA methylation, DNA strand breaks, and uracil incorporation into DNA) in blood mononuclear cells in these patients.

Secondary

  • Analyze the effects of these dietary interventions on the patterns of differential gene expression in rectal epithelial cells and blood mononuclear cells in these patients.

OUTLINE: This is a randomized, single-blind study.

  • Run-in period: Patients are placed on an average folate-containing diet for 56 days.
  • Randomization: After completion of the run-in period, patients are randomized to 1 of 2 arms.
  • Arm I (folate depleted diet): Patients are placed on a low-folate diet for 84 days. Patients receive oral folic acid supplementation once daily on days 57-84.
  • Arm II (folate supplemented diet): Patients continue on an average folate-containing diet for an additional 56 days. Patients receive oral folic acid supplementation once daily on days 1-56.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 20 patients (10 per arm) will be accrued for this study within 2.5 years.

Being tested
dietary intervention, folic acid
Keywords
colon cancer, rectal cancer
Medical subject headings
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dietary interventionDietary supplement

    oral folic acid supplementation once daily on days 57-84

  • folic acidDietary supplement

    oral folic acid supplementation once daily on days 1-56.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. •Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints

    Measured: pre and post treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Nov 2004 (estimated)
  2. Study startSep 2004
  3. Primary completionFeb 2007
  4. Study completionMar 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00096330
Sponsor's protocol ID
CDR0000393455
Other IDs
P30CA016056, RUH-PHO-0514-0404, RPCI-EPR-20703, AECM-0401022E, NEMCH-6060
Status last verified
Jan 2014
First submitted
9 Nov 2004
Last updated
13 Jan 2014
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing dietary intervention and folic acid in people with Colorectal Cancer, run by Roswell Park Cancer Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

•Analyze the effects of a folate-depleted vs a folate-supplemented diet on folate-related DNA endpoints (time frame: pre and post treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in